Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24246295 | 0.78 | CYP3A4 (0.53) | CYP3A4TDP1MEN1KMT2ACYP2C19 | |
| SCHEMBL23106913 | 0.76 | CYP19A1 (0.36) | CYP3A4TDP1CYP2C19CYP2C9CYP19A1 | |
| SCHEMBL23090523 | 0.67 | HPGD (0.30) | — | |
| SCHEMBL24246305 | 0.67 | HPGD (0.30) | — | |
| SCHEMBL23106867 | 0.65 | SHBG (0.44) | CYP3A4MEN1KMT2ACYP17A1CYP19A1 | |
| SCHEMBL24246306 | 0.65 | SHBG (0.44) | CYP3A4MEN1KMT2ACYP17A1CYP19A1 | |
| SCHEMBL24246204 | 0.63 | SMN1; SMN2 (0.34) | CYP2C19CYP19A1 | |
| SCHEMBL23106956 | 0.63 | SMN1; SMN2 (0.34) | CYP2C19CYP19A1 | |
| SCHEMBL23106927 | 0.63 | SMN1; SMN2 (0.34) | CYP2C19CYP19A1 | |
| SCHEMBL13347821 | 0.63 | CYP3A4 (0.58) | CYP3A4TDP1MEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018006-B2 | Method of producing EPD and analogues thereof | VAN HAAFTEN CAROLINE (NL) | 2024-06-25 | — | — | US | disclosed |
| US-20210078965-A1 | METHOD OF PRODUCING EPD AND ANALOGUES THEREOF | VAN HAAFTEN CAROLINE (NL) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018006-B2 | Method of producing EPD and analogues thereof | EPX, EPB41, ERG28 | CYP3A4 347/4885TDP1 3269/4885MEN1 1546/4885 |
| US-20210078965-A1 | METHOD OF PRODUCING EPD AND ANALOGUES THEREOF | EPX, EPB41, ERG28 | CYP3A4 347/4885TDP1 3269/4885MEN1 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.